Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen Rhinoconjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Written consent~* Grass-pollen related allergic rhinoconjunctivitis for at least the last 2 pollen seasons.~* Sensitised to grass pollen (positive SPT and RAST level of at least class 2).~* Total symptom score of the RRTSS during the previous pollen season greater than or equal to 12.~* Safety laboratory resuts within the references ranges~Exclusion Criteria:~* Pregnancy, breast-feeding/lactation~* Had received desensitisation treatment for grass pollen~* Treatment by immunotherapy with another allergen within the previous 5 years~* Usual contraindications of immunotherapy such as serious immunopathologic conditions or malignancies~* Treated with beta-blockers or under continuous corticotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 100 IR (Type: EXPERIMENTAL): 100 IR grass pollen allergen extract tablet
- 300 IR (Type: EXPERIMENTAL): 300 IR grass pollen allergen extract tablet
- 500 IR (Type: EXPERIMENTAL): 500 IR grass pollen allergen extract tablet
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).